CCTG

BR.34

NCT03057106

BR.34

A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC)

Status:

Closed to Accrual

26459-200.png

II

Phase

Line of Therapy.png

2nd

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

EGFR

Investigational

Product

Durvalumab

IgG1k monoclonal antibody

Treatment Arms

o Active Comparator: Durvalumab and Tremelimumab

o Active Comparator: Platinum based chemotherapy + Durvalumab + Tremelimumab